Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up.

Abstract

Tyrosine kinase inhibitors have dramatically improved the prognosis of metastatic renal cell carcinoma (RCC). However, it remains unknown whether treatment should be continued until progression or discontinued in patients with good response. We present the history of a woman diagnosed with RCC in 1997, who started sorafenib in 2004, two years after the occurrence of lung and mediastinal metastases. Over the following 8 years, the sorafenib dose was reduced at least 3 times due to toxicity and the treatment was discontinued twice upon the patient's decision, from May 2005 to March 2009, then from January 2011 to August 2011. The last evaluation in January 2013 showed stable disease. This case illustrates the feasibility of treatment discontinuation without negative impact on survival, as previously shown by some authors.

• Authors: Mathilde Guerin, Naji Salem, Jochen Walz, Slimane Dermeche, Gwenaelle Gravis
• Journal: World journal of surgical oncology (World J Surg Oncol) Vol. 11 Pg. 243 (Sep 27 2013) ISSN: 1477-7819 [Electronic] England
• PMID: 24073932 (Publication Type: Case Reports, Journal Article)

Chemical References

• Phenylurea Compounds
• Protein Kinase Inhibitors
• Niacinamide
• Sorafenib

Topics

• Adult
• Brain Neoplasms (drug therapy, secondary)
• Carcinoma, Renal Cell (drug therapy, pathology)
• Disease Progression
• Female
• Follow-Up Studies
• Humans
• Kidney Neoplasms (drug therapy, pathology)
• Lung Neoplasms (drug therapy, secondary)
• Mediastinal Neoplasms (drug therapy, secondary)
• Niacinamide (analogs & derivatives, therapeutic use)
• Phenylurea Compounds (therapeutic use)
• Protein Kinase Inhibitors (therapeutic use)
• Sorafenib
• Treatment Outcome